179 related articles for article (PubMed ID: 34919963)
1. The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation.
Zeng Q; Lu W; Deng Z; Zhang B; Wu J; Chai J; Chen X; Xu X
J Biol Chem; 2022 Jan; 298(1):101497. PubMed ID: 34919963
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory effects of FS48, the first potassium channel inhibitor from the salivary glands of the flea Xenopsylla cheopis.
Deng Z; Zeng Q; Tang J; Zhang B; Chai J; Andersen JF; Chen X; Xu X
J Biol Chem; 2021; 296():100670. PubMed ID: 33864815
[TBL] [Abstract][Full Text] [Related]
3. Acacetin blocks kv1.3 channels and inhibits human T cell activation.
Zhao N; Dong Q; Fu XX; Du LL; Cheng X; Du YM; Liao YH
Cell Physiol Biochem; 2014; 34(4):1359-72. PubMed ID: 25301362
[TBL] [Abstract][Full Text] [Related]
4. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Ye F; Hu Y; Yu W; Xie Z; Hu J; Cao Z; Li W; Wu Y
Toxins (Basel); 2016 Apr; 8(4):115. PubMed ID: 27104568
[TBL] [Abstract][Full Text] [Related]
5. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
[TBL] [Abstract][Full Text] [Related]
6. The
Xiong W; Fan H; Zeng Q; Deng Z; Li G; Lu W; Zhang B; Lai S; Chen X; Xu X
Acta Pharm; 2023 Mar; 73(1):145-155. PubMed ID: 36692462
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.
Zhao N; Dong Q; Qian C; Li S; Wu QF; Ding D; Li J; Wang BB; Guo KF; Xie JJ; Cheng X; Liao YH; Du YM
Sci Rep; 2015 Nov; 5():17381. PubMed ID: 26616555
[TBL] [Abstract][Full Text] [Related]
8. 18β-Glycyrrhetinic acid potently inhibits Kv1.3 potassium channels and T cell activation in human Jurkat T cells.
Fu XX; Du LL; Zhao N; Dong Q; Liao YH; Du YM
J Ethnopharmacol; 2013 Jul; 148(2):647-54. PubMed ID: 23707333
[TBL] [Abstract][Full Text] [Related]
9. K
Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
[TBL] [Abstract][Full Text] [Related]
10. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
11. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
12. Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway.
Fellerhoff-Losch B; Korol SV; Ganor Y; Gu S; Cooper I; Eilam R; Besser M; Goldfinger M; Chowers Y; Wank R; Birnir B; Levite M
J Neural Transm (Vienna); 2016 Mar; 123(3):137-57. PubMed ID: 26611796
[TBL] [Abstract][Full Text] [Related]
13. Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells.
Zhao N; Dong Q; Du LL; Fu XX; Du YM; Liao YH
PLoS One; 2013; 8(5):e64629. PubMed ID: 23717641
[TBL] [Abstract][Full Text] [Related]
14. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
15. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
[TBL] [Abstract][Full Text] [Related]
16. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
18. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
19. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP
J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724
[TBL] [Abstract][Full Text] [Related]
20. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
